# Immunocore Holdings plc (IMCR) FY2026 Q2 P&L / Income Statement

- Company: Immunocore Holdings plc (IMCR)
- Period: 2026-04-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-06, accession number 0001671927-26-000022
- Page: https://plicit.ai/financials/imcr/fy2026-q2-income-statement
- Chart image: https://plicit.ai/charts/imcr-fy2026-q2-income-statement-sankey.png

## Chart details: Revenue by Product and Service by Geography

Income statement for 2026-04-01 through 2026-06-30. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenue**: 115,927,000 US dollars
- **Cost of revenue from sale of therapies**: 1,088,000 US dollars
- **Gross profit (calculated)**: 114,839,000 US dollars
- **Operating expenses (calculated)**: 117,835,000 US dollars
- **Income (loss) from operations**: negative 2,996,000 US dollars
- **Other income (expense), net (calculated)**: 2,482,000 US dollars
- **Net income (loss) before income taxes**: negative 514,000 US dollars
- **Income tax expense**: 294,000 US dollars
- **Net income (loss)**: negative 808,000 US dollars
- **Revenue from sale of therapies, net - UNITED STATES**: 74,937,000 US dollars
- **Revenue from sale of therapies, net - International**: 6,866,000 US dollars
- **Revenue from sale of therapies, net - Europe**: 34,124,000 US dollars
- **Research and development expense**: 73,945,000 US dollars
- **Selling, general and administrative expense**: 43,890,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.